Possibility for the use of bromhexine to prevent infection with SARS-CoV-2
https://doi.org/10.37489/2588-0519-2020-S4-8-10
Abstract
The routine use of bromhexine to prevent infection SARS-CoV-2 is not recommended. The use of bromhexine is possible in clinical trials.
About the Authors
K. A. Zagorodnikova
National Medical Research Center named after V.A. Almazov of the Ministry of Health of Russia
Russian Federation
Russian Federation
Zagorodnikova Ksenia A. – Candidate of Medical Sciences, PhD, Head of the Department of Clinical Pharmacology. SPIN code: 4669-2059
St. Petersburg
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology. SPIN code: 8308-7599
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. Ishiguro N, Senda C, Kishimoto W, Sakai K, Funae Y, Igarashi T. Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica. 2000;30(1):71-80. DOI:10.1080/004982500237839
2. Liu J. (2014). Bromhexine. In Handbook of Metabolic Pathways of Xenobiotics (eds P.W. Lee, H. Aizawa, L.L. Gan, C. Prakash and D. Zhong). DOI:10.1002/9781118541203.xen126
3. Lucas JM, Heinlein C, Kim T et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4(11):1310-1325. DOI:10.1158/2159-8290.CD-13-1010
4. Meng T, Cao H, Zhang H et al. The insert sequence in SARSCoV-2 enhances spike protein cleavage by TMPRSS. 2020; bioRxiv DOI:10.1101/2020.02.08.926006
5. Maggio R, Corsini GU. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection [published online ahead of print, 2020 Apr 22]. Pharmacol Res. 2020;104837. DOI:10.1016/j.phrs.2020.104837
6. S1: Chymotrypsin: transmembrane serine protease 2. Last modified on 30/03/2020. Accessed on 29/04/2020. IUPHAR/BPS Guide to pharmacology, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421
7. Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, Matsuda Z. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob. Agents Chemother. 2016;60(11):6532-6539. DOI: 10.1128/AAC.01043-16
8. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052
9. Sonawane Kailas, Barale Sagar S et al. Homology Modeling and Docking Studies of TMPRSS2 with experimentally Known Inhibitors Camostat Mesylate, Nafamostat and Bromhexine Hydrochloride to Control SARS-Coronavirus-2. ChemRxiv. 2020. Preprint. DOI: 10.26434/chemrxiv.12162360.v1
10. http://grls.rosminzdrav.ru
11. Bechgaard E, Nielsen A. Bioavailability of bromhexine tablets and preliminary pharmacokinetics in humans. Biopharm Drug Dispos. 1982;3(4):337-344. DOI:10.1002/bdd.2510030407
Review
For citations:
Zagorodnikova K.A., Mirzaev K.B., Sychev D.A. Possibility for the use of bromhexine to prevent infection with SARS-CoV-2. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):8-10. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-8-10
Views:
14871
Email this article 